According to the most recent reported 13F filings, institutional investors showed notable buying activity in Eli Lilly & Co. (LLY), with several prominent quantitative managers, global asset managers, and hedge funds increasing their positions during the quarter. The buying comes as Eli Lilly continues to strengthen its position as one of the world’s leading pharmaceutical companies, driven by strong demand for its diabetes, obesity, and oncology treatments, alongside a promising pipeline of new medicines.
Below are the most notable buyers from the latest reported quarter:
Cliff Asness
Shares: 855,420 Change: +348,581 Value: $0.79B
AQR Capital Management recorded the largest increase among the investors shown, adding more than 348,000 shares during the quarter. The sizeable purchase reflects the firm’s systematic investment approach, which combines valuation, quality, profitability, and momentum factors across global equity markets.
Ken Fisher
Shares: 4,838,986 Change: +232,659 Value: $4.45B
Fisher Asset Management significantly increased its already substantial Eli Lilly position. With nearly 4.84 million shares valued at approximately $4.45 billion, the firm remains by far the largest holder among the investors listed, highlighting continued confidence in Lilly’s long-term growth prospects.
Steve Cohen
Shares: 95,766 Change: +28,020 Value: $0.09B
Point72 Asset Management increased its Eli Lilly holdings during the quarter by more than 28,000 shares. The addition suggests the firm continues to see attractive opportunities in one of the pharmaceutical sector’s strongest performers.
Jeremy Grantham
Shares: 749,815 Change: +10,541 Value: $0.69B
GMO modestly increased its position in Eli Lilly during the quarter. The purchase is consistent with Jeremy Grantham’s long-term investment philosophy of owning high-quality businesses with durable competitive advantages.
Joel Greenblatt
Shares: 16,175 Change: +4,867 Value: $0.01B
Gotham Asset Management added to its Eli Lilly position during the quarter. The increase aligns with Greenblatt’s disciplined quantitative value strategy, which emphasizes companies generating strong returns on capital.
Mario Gabelli
Shares: 26,339 Change: +1,463 Value: $0.02B
GAMCO Investors modestly increased its Eli Lilly stake. The purchase is consistent with Mario Gabelli’s long-standing focus on identifying companies with attractive long-term business value.
Overall Takeaway
Collectively, these filings highlight continued institutional interest in Eli Lilly shares. The largest additions came from AQR Capital Management and Fisher Asset Management, while several other respected investment firms, including Point72, GMO, Gotham Asset Management, and GAMCO Investors, also increased their exposure.
The broad-based buying across quantitative managers, growth-oriented investors, and value-focused firms suggests continued confidence in Eli Lilly’s long-term earnings potential, supported by its leadership in obesity and diabetes treatments and a robust pharmaceutical pipeline. Although Bridgewater modestly reduced its stake, the overall pattern of institutional activity remains decidedly positive.
Comments
Log in or sign up to join the conversation.